Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Silence Therapeutics pleased with pipeline progress of Quark Pharma

Quark has dosed the first patient in a phase III trial of its QPI-1002 drug which uses Silence’s chemical modification technology
scientist with a microscope
If the drug is a success, Silence stands to receive royalties from Quark

An Israeli pharma group which has licensed Silence Therapeutics PLC's (LON:SLN) chemical modification technology has dosed the first patient in a phase III trial of its acute kidney injury treatment.

Quark Pharmaceuticals also announced it has reached an agreement with the US Food and Drug Administration on the overall study design with a new primary endpoint.

Silence is eligible to receive either approximately 1.5%-4% royalties from Quark on the QPI-1002 drug plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

“We are pleased to see the pipeline progress made by Quark Pharmaceuticals,” said Silence executive chair Annalisa Jenkins.

“Based upon positive data observed in their phase II programme, Quark have successfully transitioned to a major pivotal phase III programme for patients at high risk post cardiac surgery requiring prevention of Acute Kidney Injury (AKI).

“This significant global siRNA programme includes proprietary chemical modification technology developed by Silence Therapeutics.”

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use